REFERENCE
GlaxoSmithKline.Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R). Media Release: 9 Jun 2008. Available from: URL: http://www.gsk.com
Rights and permissions
About this article
Cite this article
Rosiglitazone [Avandia] does not increase the risk of cardiovascular mortality and morbidity in patients with type 2 diabetes mellitus. React. Wkly. 1206, 5 (2008). https://doi.org/10.2165/00128415-200812060-00016
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-200812060-00016